Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML
NCT06268574
·
clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
94
Enrollment
INDUSTRY
Sponsor class
Conditions
Acute Myeloid Leukemia (AML)
High-risk Myelodysplastic Syndrome
Interventions
DRUG:
RVU120
Sponsor
Ryvu Therapeutics SA